Severe pneumonia by aciclovir-resistant varicella-zoster virus during etanercept therapy

Authors:

Abstract
Sir, Patients treated with antagonists of TNF-α (anti-TNF-α) are at increased risk of bacterial infections [1]. Compared with bacterial infection, little is known about the risk of viral infections in patients undergoing therapy with anti-TNF-α agents. Immunodeficiency is known to trigger the reactivation of varicella-zoster virus (VZV), one of the most common adverse events reported in clinical trials of anti-TNF-α agents [1]. Recent studies observed a mildly increased risk of herpes zoster reactivation in patients treated with anti-TNF-α agents [2–4]. Nevertheless, therapy with the anti-TNF-α agent etanercept was not associated with an enhanced risk of herpes zoster [2, 3].